The Yin and Yang of interleukin-2 - Mediated immunotherapy

New England Journal of Medicine

Volumn 365, Issue 22, 2011, Pages 2129-2131

  Bluestone, Jeffrey A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER RELAPSE; CELL ACTIVATION; CELL COUNT; CELL EXPANSION; CELL FUNCTION; CELL MATURATION; CELL SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG MEGADOSE; EDITORIAL; HUMAN; IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA; LOW DRUG DOSE; LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; TREATMENT RESPONSE;

EID: 82555192217     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1110900     Document Type: Editorial

References (11)

1. Koreth J, Matsuoka K-i, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:2055-66.
2. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067-77.
3. Rosenberg SA, Lotze MT. Cancer immunotherapy using interleukin- 2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 1986;4:681-709.
4. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010;33:153-65.
5. Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008;28:687-97.
6. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775-87. (Pubitemid 351707693)
7. Allan SE, Broady R, Gregori S, et al. CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev 2008;223:391-421. (Pubitemid 351986179)
8. Trenado A, Charlotte F, Fisson S, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003;112:1688-96. (Pubitemid 38063726)
9. Shenghui Z, Yixiang H, Jianbo W, et al. Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 2011;129:1373-81.
10. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011;117:1061-70.
11. The INSIGHT-ESPRIT Study Group and SILCAAT Scientific Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009;361:1548-59.